WIRE — US-based OKAVA Pharmaceuticals started testing a long-acting implant, designed to deliver the medicine continuously for up to six months.
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.